41 research outputs found
Bilateral claw hand: An uncommon presentation of regional Guillain-Barré syndrome
We present an uncommon case of a 38-year-old man presented with bilateral subacute weakness of intrinsic hand muscles, manifesting as bilateral claw-hand, without sensory deficits and absent tendon reflexes in upper arms. Nerve conduction studies showed findings consistent with demyelinating GBS. During the fourth day of hospitalization the patient presented symmetrical distal leg weakness and was treated with intravenous immunoglobulin. © 2013 Elsevier B.V
The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
Background The aim of the present meta-analysis was to evaluate the effect of disease-modifying drugs (DMD) on brain atrophy in patients with relapsing-remitting multiple sclerosis (RRMS) using available randomized-controlled trial (RCT) data. Methods We conducted a systematic review and meta-analysis according to PRISMA guidelines of all available RCTs of patients with RRMS that reported data on brain volume measurements during the study period. Results We identified 4 eligible studies, including a total of 1819 RRMS patients (71% women, mean age 36.5 years, mean baseline EDSS-score: 2.4). The mean percentage change in brain volume was found to be significantly lower in DMD versus placebo subgroup (standardized mean difference:-0.19; 95%CI:-0.27-0.11; p<0.001). We detected no evidence of heterogeneity between estimates (I2 = 30%, p = 0.19) nor publication bias in the Funnel plots. Sensitivity analyses stratifying studies according to brain atrophy neuroimaging protocol disclosed no evidence of heterogeneity (p = 0.16). In meta-regression analyses, the percentage change in brain volume was found to be inversely related with duration of observation period in both DMD (meta-regression slope =-0.03; 95% CI:-0.04-0.02; p<0.001) and placebo subgroups (meta-regression slope =-0.05; 95% CI:-0.06-0.04; p<0.001). However, the rate of percentage brain volume loss over time was greater in placebo than in DMD subgroup (p = 0.017, ANCOVA). Conclusions DMD appear to be effective in attenuating brain atrophy in comparison to placebo and their benefit in delaying the rate of brain volume loss increases linearly with longer treatment duration. © 2015 Tsivgoulis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis
[No abstract available
Extracranial venous hemodynamics in multiple sclerosis A case-control study
Objectives: A chronic state of impaired cerebral and cervical venous
drainage, termed chronic cerebrospinal venous insufficiency (CCSVI), has
recently been implicated in the pathogenesis of multiple sclerosis (MS).
We performed a color-coded Doppler sonography case-control study to
externally validate the CCSVI criteria.
Methods: We prospectively evaluated consecutive patients with clinically
definite MS and healthy volunteers using extracranial and transcranial
color-coded Doppler sonography. The recently developed neurosonology
criteria for CCSVI detection were used for interpretation of ultrasound
assessments. The presence of venous reflux in cervical veins was
assessed both in the sitting and upright position during a short period
of apnea and after Valsalva maneuver.
Results: We recruited 42 patients with MS (mean age 39 +/- 11 years, 17
men) and 43 control individuals (mean age 38 +/- 12 years, 16 men). Very
good/excellent intrarater and interrater agreement (kappa values
0.82-1.00) was documented in 3 out of 5 CCSVI criteria. There was no
evidence of stenosis or nondetectable Doppler flow in cervical veins in
patients and controls. Reflux in internal jugular vein (IJV) was
documented in 1 patient (2%) and 1 control subject (2%), both in
sitting and supine posture during apnea. After performing Valsalva
maneuver, we documented the presence of IJV valve incompetence in 3
patients with MS (7%) and 4 healthy volunteers (9%; p > 0.999).
Conclusions: With established reproducibility of venous ultrasound
testing, our data argue against CCSVI as the underlying mechanism of MS.
Without further independent validation of CCSVI, potentially dangerous
endovascular procedures, proposed as novel therapy for MS, should not be
performed outside controlled clinical trials. Neurology (R) 2011; 77:
1241-124
Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis
[No abstract available
Influence of sleep disturbance on quality of life of patients with epilepsy
SummaryThe frequency of sleep disturbances in patients with epilepsy and their impact on quality of life (QoL) have been documented in a few reports, and the results are conflicting. We identified 124 consecutive epilepsy out-patients who visited the epilepsy out-patient clinics at the University Hospital of Alexandroupolis, the AHEPA Hospital in Thessaloniki and the Aeginitio Hospital in Athens. We measured excessive daytime sleepiness (EDS) with the Epworth Sleepiness Scale (ESS), obstructive sleep apnea (OSA) with the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ), and insomnia with the Athens Insomnia Scale (AIS). We evaluated quality of life by the Quality of Life in Epilepsy Inventory (QOLIE-31). EDS was found in 16.9% (21/124) of epileptic patients, OSA in 28.2% (35/124), and insomnia in 24.6% (30/122). In multivariate analysis, we found that insomnia was an independent negative factor for Total score (p<0.001), Overall QoL (p=0.002), Emotional well-being (p<0.001), Energy/fatigue (p<0.001), Cognitive functioning (p=0.04) and Social functioning (p=0.03), and OSA only for Cognitive functioning (p=0.01). According to our findings, EDS, OSA, and insomnia are frequent in epileptic patients. Epileptic patients with sleep disturbance, mainly insomnia, have significant QoL impairment